US equities
|
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sight Sciences, Inc. - Common Stock
(NQ:
SGHT
)
8.965
+0.075 (+0.84%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sight Sciences, Inc. - Common Stock
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
May 08, 2025
From
Sight Sciences, Inc.
Via
GlobeNewswire
Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
June 21, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical
May 23, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
May 06, 2023
Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract...
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
May 04, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
May 01, 2023
Clinical data includes long-term trial results and robust real-world comparative data from IRIS® Registry
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
April 26, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
April 20, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023
April 13, 2023
The event will include presentations from leading glaucoma surgeons and remarks from the Sight Sciences executive management team
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
April 03, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
March 30, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
March 09, 2023
The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
February 23, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
February 22, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Announces 1,000th TearCare® Customer Installation
January 26, 2023
Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD)
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
January 09, 2023
Company Also Announces CFO Transition
From
Sight Sciences, Inc.
Via
GlobeNewswire
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
December 08, 2022
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Reports Third Quarter 2022 Financial Results
November 10, 2022
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
November 03, 2022
Multicenter Clinical Data from Five US sites Published in International Ophthalmology
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
October 20, 2022
From
Sight Sciences, Inc.
Via
GlobeNewswire
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
September 29, 2022
From
Sight Sciences, Inc.
Via
GlobeNewswire
